Clinical Trials
36 trialsAdaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
Nanfang Hospital, Southern Medical University
CONVERGENCE
National University Hospital, Singapore
OMEC-5
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
DETERMINE
Cancer Research UK
SNCCTGC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PLASTIC-3
Leiden University Medical Center
Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression
Second Affiliated Hospital of Nanchang University
OCTASUR
Ukrainian Society of Clinical Oncology
FAPIDO
KU Leuven
CHANGE
Shanghai University of Traditional Chinese Medicine
Study of Tislelizumab in Combination With SOX for the Treatment of Gastric Cancer With Liver Metastases
Zhejiang University
HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy
Tongji Hospital
RAMSES/FLOT7
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)
ASLAN Pharmaceuticals
Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis
Ruijin Hospital
RusGCG-01
Blokhin's Russian Cancer Research Center
RJGC-Senile
Ruijin Hospital
PETRARCA
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Perioperative Chemotherapy for Potentially Resectable Gastric Cancer
Hebei Medical University
5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
Krankenhaus Nordwest
HIPECStomach
University Hospital Tuebingen
Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor
Sun Yat-sen University
Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer
Hebei Medical University
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
Hebei Medical University
A Efficacy and Tolerability Study of TEGAFOX Sequential S-1 in the Treatment of Adjuvant Chemotherapy for Gastric Cancer
LanZhou University
A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer
Shanghai Zhongshan Hospital
Comparison of Surgical,Clinical and Oncological Outcomes Between Robotic-assisted and Laparoscopic-assisted Gastrectomy
Chinese PLA General Hospital
TOF Versus SOX in Metastatic Gastric Cancer
The First People's Hospital of Changzhou
The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer
First Affiliated Hospital, Sun Yat-Sen University
STOPEROPCHEM
Medical University of Lublin
TMGS
Tribhuvan University Teaching Hospital, Institute Of Medicine.
Roux-en-Y Versus Billroth II Reconstruction After Subtotal Gastrectomy in Gastric Cancer Comorbid With Type II Diabetes
Xiamen University
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Fudan University
Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer
Japan Clinical Cancer Research Organization
BREC-AGC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
eNCIT-Japan
Eastern Network of Cancer Immunological Therapy, Japan